# Physiology

## Demography of Raltegravir 10 mg (lactose formulation) vs. simulated Healthy Adult Population

Figure : Distribution of age for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 10 mg (lactose formulation).



Figure : Distribution of body weight for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 10 mg (lactose formulation).



Figure : Distribution of body height for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 10 mg (lactose formulation).



Figure : Distribution of BMI for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 10 mg (lactose formulation).



Figure : Distribution of body surface area for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 10 mg (lactose formulation).



Figure : Distribution of gender for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 10 mg (lactose formulation).



## Demography of Raltegravir 25 mg (lactose formulation) vs. simulated Healthy Adult Population

Figure : Distribution of age for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 25 mg (lactose formulation).



Figure : Distribution of body weight for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 25 mg (lactose formulation).



Figure : Distribution of body height for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 25 mg (lactose formulation).



Figure : Distribution of BMI for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 25 mg (lactose formulation).



Figure : Distribution of body surface area for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 25 mg (lactose formulation).



Figure : Distribution of gender for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 25 mg (lactose formulation).



## Demography of Raltegravir 50 mg (lactose formulation) vs. simulated Healthy Adult Population

Figure : Distribution of age for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 50 mg (lactose formulation).



Figure : Distribution of body weight for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 50 mg (lactose formulation).



Figure : Distribution of body height for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 50 mg (lactose formulation).



Figure : Distribution of BMI for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 50 mg (lactose formulation).



Figure : Distribution of body surface area for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 50 mg (lactose formulation).



Figure : Distribution of gender for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 50 mg (lactose formulation).



## Demography of Raltegravir 100 mg (lactose formulation) vs. simulated Healthy Adult Population

Figure : Distribution of age for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 100 mg (lactose formulation).



Figure : Distribution of body weight for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 100 mg (lactose formulation).



Figure : Distribution of body height for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 100 mg (lactose formulation).



Figure : Distribution of BMI for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 100 mg (lactose formulation).



Figure : Distribution of body surface area for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 100 mg (lactose formulation).



Figure : Distribution of gender for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 100 mg (lactose formulation).



## Demography of Raltegravir 200 mg (lactose formulation) vs. simulated Healthy Adult Population

Figure : Distribution of age for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 200 mg (lactose formulation).



Figure : Distribution of body weight for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 200 mg (lactose formulation).



Figure : Distribution of body height for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 200 mg (lactose formulation).



Figure : Distribution of BMI for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 200 mg (lactose formulation).



Figure : Distribution of body surface area for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 200 mg (lactose formulation).



Figure : Distribution of gender for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 200 mg (lactose formulation).



## Demography of Raltegravir 400mg (lactose formulation) vs. simulated Healthy Adult Population

Figure : Distribution of age for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 400mg (lactose formulation).



Figure : Distribution of body weight for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 400mg (lactose formulation).



Figure : Distribution of body height for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 400mg (lactose formulation).



Figure : Distribution of BMI for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 400mg (lactose formulation).



Figure : Distribution of body surface area for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 400mg (lactose formulation).



Figure : Distribution of gender for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 400mg (lactose formulation).



## Demography of Raltegravir 800 mg (lactose formulation) vs. simulated Healthy Adult Population

Figure : Distribution of age for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 800 mg (lactose formulation).



Figure : Distribution of body weight for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 800 mg (lactose formulation).



Figure : Distribution of body height for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 800 mg (lactose formulation).



Figure : Distribution of BMI for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 800 mg (lactose formulation).



Figure : Distribution of body surface area for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 800 mg (lactose formulation).



Figure : Distribution of gender for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 800 mg (lactose formulation).



## Demography of Raltegravir 1200 mg (lactose formulation) vs. simulated Healthy Adult Population

Figure : Distribution of age for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 1200 mg (lactose formulation).



Figure : Distribution of body weight for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 1200 mg (lactose formulation).



Figure : Distribution of body height for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 1200 mg (lactose formulation).



Figure : Distribution of BMI for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 1200 mg (lactose formulation).



Figure : Distribution of body surface area for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 1200 mg (lactose formulation).



Figure : Distribution of gender for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 1200 mg (lactose formulation).



## Demography of Raltegravir 1600 mg (lactose formulation) vs. simulated Healthy Adult Population

Figure : Distribution of age for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 1600 mg (lactose formulation).



Figure : Distribution of body weight for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 1600 mg (lactose formulation).



Figure : Distribution of body height for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 1600 mg (lactose formulation).



Figure : Distribution of BMI for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 1600 mg (lactose formulation).



Figure : Distribution of body surface area for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 1600 mg (lactose formulation).



Figure : Distribution of gender for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 1600 mg (lactose formulation).



## Demography of Raltegravir 100 mg filmcoated tablet md vs. simulated Healthy Adult Population

Figure : Distribution of age for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 100 mg filmcoated tablet md.



Figure : Distribution of body weight for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 100 mg filmcoated tablet md.



Figure : Distribution of body height for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 100 mg filmcoated tablet md.



Figure : Distribution of BMI for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 100 mg filmcoated tablet md.



Figure : Distribution of body surface area for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 100 mg filmcoated tablet md.



Figure : Distribution of gender for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 100 mg filmcoated tablet md.



## Demography of Raltegravir 200 mg filmcoated tablet md vs. simulated Healthy Adult Population

Figure : Distribution of age for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 200 mg filmcoated tablet md.



Figure : Distribution of body weight for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 200 mg filmcoated tablet md.



Figure : Distribution of body height for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 200 mg filmcoated tablet md.



Figure : Distribution of BMI for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 200 mg filmcoated tablet md.



Figure : Distribution of body surface area for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 200 mg filmcoated tablet md.



Figure : Distribution of gender for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 200 mg filmcoated tablet md.



## Demography of Filmcoated\_tablet\_400mg\_sd vs. simulated Healthy Adult Population

Figure : Distribution of age for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 400mg filmcoated tablet.



Figure : Distribution of body weight for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 400mg filmcoated tablet.



Figure : Distribution of body height for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 400mg filmcoated tablet.



Figure : Distribution of BMI for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 400mg filmcoated tablet.



Figure : Distribution of body surface area for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 400mg filmcoated tablet.



Figure : Distribution of gender for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 400mg filmcoated tablet.



## Demography of Raltegravir 400 mg filmcoated tablet md vs. simulated Healthy Adult Population

Figure : Distribution of age for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 400 mg filmcoated tablet md.



Figure : Distribution of body weight for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 400 mg filmcoated tablet md.



Figure : Distribution of body height for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 400 mg filmcoated tablet md.



Figure : Distribution of BMI for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 400 mg filmcoated tablet md.



Figure : Distribution of body surface area for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 400 mg filmcoated tablet md.



Figure : Distribution of gender for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 400 mg filmcoated tablet md.



## Demography of Raltegravir 400mg chewable fasted vs. simulated Healthy Adult Population

Figure : Distribution of age for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 400mg chewable fasted.



Figure : Distribution of body weight for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 400mg chewable fasted.



Figure : Distribution of body height for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 400mg chewable fasted.



Figure : Distribution of BMI for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 400mg chewable fasted.



Figure : Distribution of body surface area for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 400mg chewable fasted.



Figure : Distribution of gender for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 400mg chewable fasted.



## Demography of Raltegravir 400mg chewable fed vs. simulated Healthy Adult Population

Figure : Distribution of age for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 400mg chewable fed.



Figure : Distribution of body weight for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 400mg chewable fed.



Figure : Distribution of body height for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 400mg chewable fed.



Figure : Distribution of BMI for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 400mg chewable fed.



Figure : Distribution of body surface area for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 400mg chewable fed.



Figure : Distribution of gender for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 400mg chewable fed.



## Demography of Raltegravir 400mg (granules in suspension) vs. simulated Healthy Adult Population

Figure : Distribution of age for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 400mg (granules in suspension).



Figure : Distribution of body weight for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 400mg (granules in suspension).



Figure : Distribution of body height for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 400mg (granules in suspension).



Figure : Distribution of BMI for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 400mg (granules in suspension).



Figure : Distribution of body surface area for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 400mg (granules in suspension).



Figure : Distribution of gender for simulated Healthy Adult Population in comparison to observed data Observed\_Raltegravir 400mg (granules in suspension).

